Asthma is a heterogenous disease, and its prevalence and severity are different in males
versus females through various ages. As children, boys have an increased prevalence of …

Rhinovirus infections can cause wheezing illnesses in all age groups. In preschool children,
rhinovirus infections frequently initiate acute wheezing illnesses. Children who wheeze with …

Background No consensus exists on how to reduce oral corticosteroids after the initiation of
biologics in severe asthma. The PONENTE trial evaluated the effectiveness and safety of a …

Background Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment
of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in …

Introduction Consensus definitions for clinical remission and super-response were recently
established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed …

Background Benralizumab is an IL-5Rα–directed monoclonal antibody indicated for patients
with severe, uncontrolled eosinophilic asthma. Objective To evaluate the long-term safety …

Background Phenotypic characteristics of patients with eosinophilic and noneosinophilic
asthma are not well characterized in global, real-life severe asthma cohorts. Research …

The functions ascribed to eosinophils have classically been limited to host defence against
certain parasitic infections and potentially deleterious effects in the setting of specific …

Introduction International registries provide opportunities to describe use of biologics for
treating severe asthma in current clinical practice. Our aims were to describe real-life global …

Asthma is a chronic inflammatory disease of the airways affecting more than 300 million
patients worldwide. The disease can be of various severity ranging from very mild to severe …